Synthesis of sol-gel silica materials providing a slow release of biphosphonate

被引:21
作者
Czuryszkiewicz, T
Areva, S
Honkanen, M
Lindén, M
机构
[1] Abo Akad Univ, Dept Chem Phys, FIN-20500 Turku, Finland
[2] Tampere Univ Technol, Inst Mat Sci, FIN-33101 Tampere, Finland
关键词
silica; spray drying; release; biphosphonate;
D O I
10.1016/j.colsurfa.2004.11.029
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
The aim of this study was to synthesize silica materials that would provide a slow release of biphosphonate. The biphosphonate used in this work, etidronate, is a small water-soluble molecule that can be used to inhibit bone resorption in the body, since calcium ions can be complexed to the biphosphonate through a bidentate bond. This kind of silica material could therefore serve as active filler in polymer-based implants. The biphosphonate was incorporated into the silica during the spray-drying step, and the silica could provide a slow release on the month time-scale. The release process is suggested to be controlled by both erosion and diffusion processes. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:69 / 74
页数:6
相关论文
共 34 条
[1]   Silica xerogel carrier material for controlled release of toremifene citrate [J].
Ahola, M ;
Kortesuo, P ;
Kangasniemi, I ;
Kiesvaara, J ;
Yli-Urpo, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 195 (1-2) :219-227
[2]   Aqueous sol-gel process for protein encapsulation [J].
Bhatia, RB ;
Brinker, CJ ;
Gupta, AK ;
Singh, AK .
CHEMISTRY OF MATERIALS, 2000, 12 (08) :2434-2441
[3]   Inclusion of ibuprofen in mesoporous templated silica:: drug loading and release property [J].
Charnay, C ;
Bégu, S ;
Tourné-Péteilh, C ;
Nicole, L ;
Lerner, DA ;
Devoisselle, JM .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2004, 57 (03) :533-540
[4]   Drug release from biodegradable silica fibers [J].
Czuryszkiewicz, T ;
Ahvenlammi, J ;
Kortesuo, P ;
Ahola, M ;
Kleitz, F ;
Jokinen, M ;
Lindén, M ;
Rosenholm, JB .
JOURNAL OF NON-CRYSTALLINE SOLIDS, 2002, 306 (01) :1-10
[5]   Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells [J].
Dumon, JC ;
Journé, F ;
Kheddoumi, N ;
Lagneaux, L ;
Body, JJ .
EUROPEAN UROLOGY, 2004, 45 (04) :521-528
[6]  
Ernst DS, 1997, J PAIN SYMPTOM MANAG, V13, P319
[7]   Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption [J].
Ezra, A ;
Golomb, G .
ADVANCED DRUG DELIVERY REVIEWS, 2000, 42 (03) :175-195
[8]   Bisphosphonates in the treatment of osteoporosis in 1997: A review [J].
Francis, RM .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1997, 58 (10) :656-678
[9]   Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound [J].
Frediani, B ;
Falsetti, P ;
Baldi, F ;
Acciai, C ;
Filippou, G ;
Marcolongo, R .
BONE, 2003, 33 (04) :575-581
[10]   Control of the morphology of nanostructured particles prepared by the spray drying of a nanoparticle sol [J].
Iskandar, F ;
Gradon, L ;
Okuyama, K .
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2003, 265 (02) :296-303